NQO1 and gastric adenocarcinoma: Similarly to NQO1, NRF2 was elevated in acute lymphoeytic leukemia, cholangiocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, glioblastoma multiforme, glioma, acute myeloid leukemia, brain lower grade glioma, liver hepatocellular carcinoma, pancreatic adenocarcinoma, stomach adenocarcinoma, stomach and esophageal carcinoma; and decreased in kidney chromophobe, kidney renal clear cell carcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, and wilms tumor (Supplementary Figure S2A).